Circulating tumor cell expression analysis from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).
Year: 2025
Type: conference-abstract
Abstract: 199 Background: Approximately 25% of patients (pts) with prostate cancer have deleterious germline/somatic homologous recombination repair mutations (HRRm). BRCAAway found the combination of an androgen receptor (AR) pathway inhibitor (ARPi) and poly(ADP-ribose) polymerase inhibitor (PARPi) as first-line therapy in pts with mCRPC and BRCA1/2 and/or ATM alterations to demonstrate longer progression-free survival (PFS) vs either agent alone or sequentially. Understanding AR signaling in HRRm (BRCA2 altered especially) versus intact patients and how they relate to response is unknown and may offer insights to mechanisms of resistance/sensitivity. Methods: Pts were randomized 1:1:1 to Arm1: abiraterone (1,000 mg)/prednisone (5 mg BID) (Abi), Arm2: olaparib (300 mg BID) (Ola), or Arm3: abiraterone/prednisone + olaparib (Abi + Ola). Internally analyzed, pooled circulating tumor cells (CTCs) were captured via bead-based EPCAM antibody with subsequent RT-PCR for gene expression profiling. Pretreatment samples from 47 pts across the three arms were compared to a historical CRPC cohort for difference and evaluated for a predictor of poor PSA response (stable PSA or progression by PCWG3). Results: A high probability of CTCs was found in 23 of 47 pts (48.9%, 11 Abi, 6 Ola, 6 Abi + Ola). In comparison to historical mCRPC pts, those with HRRm did not segregate from DNA repair intact pts regarding AR signaling. Also, PSA responders did not segregate from non-responders. Focusing on those with BRCA2 HRRm (20/23, 10 Abi, 5 Ola, 5 Abi+Ola), lack of PSA response was seen in 6/20 (30%). Combining the monotherapy cohorts, higher AR expression (median 22 for nonresponders and 15 for responders) correlated with lack of PSA response (unpaired t-test p=0.03), while ARV7 (median 18 vs 12) did not but may suffer from underpowering (p=0.20). Interestingly, the Abi+Ola cohort had a median AR expression closer to nonresponders (21.3), yet all 5 responded. Conclusions: Enriched CTC gene profiles from BRCAAway study pts prior to therapy in all arms appear similar to non HRRm mutant pts, supporting that the AR signaling pathway is consistently altered in mCRPC regardless of HRR status. For those with BRCA2 related HRRm, high AR expression associates with poor monotherapy response (Abi or Ola), but not the combination (Abi+Ola), suggesting the combination may rescue patients with AR addiction. Clinical trial information: NCT03012321 . BRCA2 cohort only (n=20) PSA ResponderMedian Gene Expression (IQR 25th/75th ) PSA NonResponder Median Gene Expression (IQR 25th/75th ) Unpaired t-test Monotherapy Cohort (Abi or Ola, n=15) AR 15.0 (13.7, 21.0) 22.0 (20.3, 23.2) P=0.03 ARV7 12.0 (3.8, 16) 18.0 (13.1, 19.7) P=0.20 Combination Cohort (Abi+Ola, n=5) AR 21.3 (20.3, 22.7) None N/A ARV7 16.3 (1.8, 18.0) None N/A
Source: Journal of Clinical Oncology
Authors: Zachery R Reichert, Maha H. A. Hussain, Jennie L Lovett, Masha Kocherginsky, Channing Judith Paller, Neeraj Agarwal, Nabil Adra, Jingsong Zhang, Joel Picus, Russell Zelig Szmulewitz, Timothy M Kuzel, Scott T. Tagawa, Latifa A Bazzi, Young E. Whang, Ryan D. Stephenson, Robert Dreicer, Daniel Shevrin, Matthew Rettig, Emmanuel S. Antonarakis, Todd Matthew Morgan
Institutions: University of Michigan, Northwestern University, U-M Rogel Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Huntsman Cancer Institute, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Moffitt Cancer Center, Washington University in St. Louis, University of Chicago, Rush University Medical Center, Cornell University, Weill Cornell Medicine, University of North Carolina at Chapel Hill, Rutgers Cancer Institute, University of Virginia, Endeavor Health, University of California, Los Angeles, University of Minnesota, Masonic Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4407699892